OakChart

CalciMedica Inc

CALCHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 8:50 AM ET

1.55+0.18 (13.14%)
2026-11-11 14:54 CET
Market cap
9.35 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-15.11 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-4.25
P/E
-
Compare

Price

CALC against its 20, 50 and 200-day averages
2050200beatearnings
5.0010.005.7M11.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CALCclose 1.5520-day 1.3350-day 1.58200-day 3.021.55

95.7% under 36.00 on 26 Dec 2025. Last 15 sessions, 62.8% high to low

Profile

CALC
52-week range, 2% of the way up
1.0036.00

CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

Employees16
IPOSep 25, 2020
Beta0.79
ATR, 14d0.19
Rel volume0.18
Short float4.14%
Insider own39.39%
Inst own34.24%

Snapshot

6 groups

Valuation

Index-
Market Cap10.58M
Enterprise Value3.71M
Income-15.11M
Sales0.00M
Book/sh0.12
Cash/sh2.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPOSep 25, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B12.65
P/C0.77
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.58
Current Ratio4.96
Debt/Eq1.63
LT Debt/Eq1.63
Option/ShortNo / Yes

Earnings

EPS (ttm)-4.25
EPS next Y-4.79
EPS next Q-0.83
EPS this Y73.60%
EPS next Y-84.10%
EPS next 5Y44.71%
EPS past 3/5Y89.18% 38.92%
Sales past 3/5Y- -
EPS Y/Y TTM47.70%
Sales Y/Y TTM-
EPS Q/Q98.13%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.81.18% -

Ownership

Insider Own39.39%
Insider Trans10.21%
Inst Own34.24%
Inst Trans19.58%
ROA-103.47%
ROE-763.32%
ROIC-135.80%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2016.87%
SMA50-1.78%
SMA200-48.68%
Trades-

Technical

Shs Outstand34.50M
Shs Float4.14M
Short Float4.14%
Short Ratio2.12
Short Interest0.17M
52W High36.00 -95.69%
52W Low1.00 55.00%
Volatility12.56% 15.19%
ATR (14)0.19
RSI (14)53.60
Beta0.79
Rel Volume0.18
Avg Volume80.92K
Volume741

Performance

Perf Week15.24%
Perf Month38.39%
Perf Quarter-52.84%
Perf Half Y-55.07%
Perf YTD-95.30%
Perf Year-90.34%
Perf 3Y-90.81%
Perf 5Y-99.29%
Perf 10Y-
Recom1.67
Target Price37.50
Prev Close1.37
Price1.55
Change %13.14%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Aug 20, 2026InitiatedGGuggenheimBuy$9+480.6%
Jan 29, 2026DowngradeHH.C. WainwrightBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
REVBRevelation Biosciences Inc2.69M
ICUSeaStar Medical Holding Corp10.31M
DMACDiaMedica Therapeutics Inc524.16M
IFRXInflaRx NV195.06M
XRTXXORTX Therapeutics Inc1.54M
UNCYUnicycive Therapeutics Inc101.95M
TENXTenax Therapeutics Inc77.35M
PALIPalisade Bio Inc198.67M
ELDNEledon Pharmaceuticals Inc225.50M
PROKProKidney Corp338.65M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Middleton Fred ADirectorJun 25 '26Buy0.80248,972199,9991,063,272Jun 29 08:45 AM

News

latest 14 of 206
  • CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates (GlobeNewswire) -9.57%
  • CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire) +5.00%
  • CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) -6.91%
  • CalciMedica Announces One-for-Five Reverse Stock Split (GlobeNewswire) -20.00%
  • CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss (InvestorsHub)
  • Loading…
  • CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates (GlobeNewswire)
  • CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints (PR Newswire)
  • CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program (PR Newswire) -25.64%
  • CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data (PR Newswire)
  • CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates (PR Newswire) +6.63%
  • CalciMedica Reports 2025 Financial Results and Provides Clinical Updates (PR Newswire) +14.44%
  • CalciMedicas stock drops 75% on acute kidney injury trial termination (Clinical Trials Arena) -18.40%
  • CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis (Benzinga) -75.59%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.240-1.275-3.4500.000.002
2026Q22026-08-11-2.250-1.425-2.2370.000.002
2026Q12026-05-121.500-1.4001.5240.000.002
2025Q42026-03-03-3.434-2.063-3.4850.000.004
2025Q32025-11-12-2.600-2.063-2.5880.000.004
2025Q22025-08-12-2.000-1.750-1.9860.000.004
2025Q12025-05-14-1.800-1.534-1.7850.000.003
2024Q42025-03-27-1.850-2.110-1.6680.000.005
2024Q32024-11-13-2.500-2.813-2.5230.000.004
2024Q22024-08-12-1.800-2.870-1.7760.000.005
2024Q12024-05-130.050-3.3380.0650.000.004
2023Q42024-03-28-3.850-4.363-3.6020.000.004
2023Q32023-11-09-4.100-5.700-4.0750.00-1
2023Q22023-08-10-5.550-5.225-5.567--2
2023Q12023-05-15-117.15-3.650-117.170.000.001
2022Q32022-11-10-32.200-28.700-31.8920.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-367.5-713.3-115.850.000.00
2021FY-118.3-114.94-118.280.000.00
2022FY-25.400-118.3-7,781-0.00
2023FY-38.300-45.788-38.2910.000.00
2024FY-6.100-7.190-6.0910.000.00
2025FY-9.850-8.513-9.8500.000.00
2026FY--2.600--0.00
2027FY--4.787--0.00
2028FY--1.665--0.00
2029FY--1.200--0.00
2030FY--1.400--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-101000.000.000.00
2026Q4S2026-08-111000.000.000.00
2026Q4S2026-05-121000.000.000.00
2026Q4S2026-03-031000.000.000.00
2026Q4R2026-05-13110-1.05-1.05-1.05
2026Q4R2026-05-12110-1.15-1.15-1.15
2026Q4R2026-03-03110-1.15-1.15-1.15
2026Q4R2025-11-12100-2.70-2.70-2.70
2026Q4R2025-11-11100-2.70-2.70-2.70
2026Q4R2025-11-10100-2.70-2.70-2.70
2026Q4E2026-11-10210-0.83-1.25-0.41
2026Q4E2026-10-25200-1.05-1.25-0.85
2026Q4E2026-08-11220-1.05-1.25-0.85
2026Q4E2026-07-01210-1.90-2.30-1.50

Estimate history

EPS, annual-113.663-153.283-115.848-118.281-7780.898-38.291-6.091-9.847-4.2472
Period20182019202020212022202320242025TTM
EPS, quarterly-2.523-1.668-1.785-1.986-2.588-3.4851.524-2.237-0.048
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.2880.2880.30.3050.0011.1512.6963.08734.5
Period20182019202020212022202320242025MRQ
Shares, quarterly2.1522.6962.7942.7942.8513.0873.1496.14734.5
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.050.060.060.050.520.400.300.17
Gross Profit0.00-0.05-0.06-0.06-0.05-0.52-0.40-0.30-0.17
Selling, General and Administrative Excl. Other18.7423.0724.1521.8214.1435.4329.4437.2028.39
Research and Development11.0015.2114.4512.368.3518.9020.9630.5822.97
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income-18.76-23.12-24.20-21.88-14.19-35.95-29.83-37.50-28.57
Interest Expense1.331.420.000.110.130.000.00--
Unusual Expense-4.306.00-9.4913.03-6.530.00-2.16-0.070.00
Net Income Before Taxes-15.11-29.56-13.70-34.36-7.82-35.82-27.53-37.04-28.38
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-15.11-29.56-13.70-34.36-9.14-35.82-27.53-37.04-28.38
Net Income From Continuing Operations-15.11-29.56-13.70-34.36-9.14-35.82-27.53-37.04-28.38
Net Income-15.11-29.56-13.70-34.36-9.14-35.82-34.72-44.09-32.70
EPS (Recurring)-0.52-8.45-9.04-28.12-11,670.75-118.28-120.89-153.46-113.66
EPS (Basic, Before Extraordinaries)-4.20-9.85-6.09-38.29-7,780.90-118.28-115.85-153.28-113.66
EPS (Diluted)-4.25-9.85-6.09-38.29-7,780.90-118.28-115.85-153.28-113.66
EBITDA--23.07-24.15-21.82-14.14-35.43-29.44-37.20-28.39
Non-Operating Income (Expense)0.680.981.010.66-0.030.130.140.390.19
Other After Tax Adjustments-0.000.000.00-1.320.000.000.000.00
Stock Option Compensation Expense-2.972.3112.041.405.381.790.740.35
Shares Outstanding34.503.092.701.150.000.310.300.290.29
Market Capitalization9.359.3547.7316.2610.7839.08608.82563.19-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.010.010.010.010.010.010.01
Gross Profit0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other4.754.005.604.385.616.616.486.16
Research and Development2.322.103.483.103.854.044.223.83
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income-4.75-4.01-5.61-4.38-5.62-6.62-6.50-6.17
Interest Expense0.360.330.320.330.330.320.450.00
Unusual Expense-3.303.60-10.806.202.00-0.50-1.70-1.70
Net Income Before Taxes-1.67-7.654.98-10.76-7.80-5.96-5.04-4.26
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.67-7.654.98-10.76-7.80-5.96-5.04-4.26
Net Income From Continuing Operations-1.67-7.654.98-10.76-7.80-5.96-5.04-4.26
Net Income-1.67-7.654.98-10.76-7.80-5.96-5.04-4.26
EPS (Recurring)-0.12-1.50-0.79-2.08-2.12-2.10-2.21-2.13
EPS (Basic, Before Extraordinaries)-0.05-2.241.57-3.48-2.59-1.99-1.79-1.67
EPS (Diluted)-0.05-2.241.52-3.48-2.59-1.99-1.79-1.67
EBITDA--4.00-5.60-4.38-5.61-6.61-6.48-6.16
Non-Operating Income (Expense)0.130.280.110.150.140.490.200.21
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.540.560.620.631.170.550.63
Shares Outstanding34.506.153.153.092.852.792.792.70
Market Capitalization9.3531.668.50101.7343.8522.3626.6947.73

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments13.0218.6711.241.4863.6795.0335.9612.83
Short Term Receivables0.000.000.000.000.020.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.511.000.370.253.394.210.320.61
Total Current Assets13.5319.6611.611.7367.0899.2436.2713.45
Net Property, Plant & Equipment0.050.120.170.201.981.921.951.49
Total Investments and Advances0.000.000.000.000.000.030.030.03
Intangible Assets---0.00-0.000.000.00
Other Assets0.010.010.411.420.030.612.412.85
Total Assets13.5919.7912.193.3569.09101.7940.6617.81
Short Term Debt Incl. Current Port. of LT Debt1.250.000.000.000.000.000.000.00
Accounts Payable1.162.000.000.000.532.514.642.52
Other Current Liabilities1.371.694.034.783.534.487.623.27
Total Current Liabilities3.783.684.034.784.067.0012.255.79
Long Term Debt8.450.000.0067.230.000.00131.3678.81
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities8.001.700.002.650.010.010.000.00
Total Liabilities20.235.384.0374.654.077.01143.6184.61
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity-6.6414.418.16-71.3065.0294.79-102.95-66.79
Total Shareholders Equity-6.6414.418.16-71.3065.0294.79-102.95-66.79
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity-6.6414.418.16-71.3065.0294.79-102.95-66.79
Total Liabilities & Stockholders Equity13.5919.7912.193.3569.09101.7940.6617.81
Book Value Per Share-2.155.347.09-59,303.51213.11316.27-357.91-232.20
Tangible Book Value Per Share-2.155.347.09-59,303.51213.11316.27-357.91-232.20
Full-Time Employees161414827312928
Price to Book Ratio11.183.311.340.260.606.426.21-
Return on Assets-177.10-85.68-132.51-25.24-41.92-38.65-126.68-
Return on Equity-761.02-121.42-155.72-70.51-44.83---
Return on Invested Capital-1,634.16-95.07-421.20--55.09-29.05-130.37-236.11
Quick Ratio3.585.342.880.3616.5314.182.962.32
Current Ratio3.585.342.880.3616.5314.182.962.32

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--29.56-13.70-34.36-7.82-35.82-27.53-37.04-28.38
Depreciation-0.050.060.060.050.520.400.300.17
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-8.96-7.018.84-4.595.43-0.370.600.37
Funds from Operations--20.55-20.65-25.46-12.36-29.87-27.50-36.14-27.84
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--0.62-0.49-0.270.60-1.63-4.564.92-0.38
Cash from Operating Activities--21.18-21.15-25.73-11.76-31.50-32.06-31.21-28.22
Capital Expenditures--0.03-0.01-0.08-0.00-0.49-1.02-0.60-1.46
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-9.58-4.428.960.0011.24-41.54-20.020.00
Purchase of Investments--15.92-29.00-6.120.00-94.57-61.64-22.520.00
Sale Or Maturity of Investments-25.5024.5915.080.00105.8120.102.500.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities-9.55-4.428.88-0.0010.75-42.56-20.62-1.46
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Change in Capital Stock-5.5527.9710.590.020.6992.1754.8742.02
Repurchase of Common Pref Stock-0.000.000.000.000.000.00-0.040.00
Sale of Common Pref Stock-5.5527.9710.590.020.6992.1754.9242.02
Proceedsfrom Stock Options-5.5227.9510.340.000.0092.0954.9242.02
Issuance or Reduction of Debt, Net-9.660.000.008.460.000.000.000.00
Change in Long Term Debt-9.660.000.008.460.000.000.000.00
Issuance of Long Term Debt-9.660.000.008.460.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.0010.310.000.000.000.000.00
Other Financing Activities Uses-0.000.00-4.540.000.000.000.000.00
Cash from Financing Activities-15.2127.9720.908.480.6992.1754.8742.02
Net Change in Cash-3.582.404.05-3.29-20.0517.553.0412.34
Free Cash Flow--21.21-21.15-25.81-11.76-31.99-33.09-31.82-29.68

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments13.7718.628.1613.0214.0817.96
Short Term Receivables-0.000.000.000.000.00
Inventories-0.000.000.000.000.00
Other Current Assets0.450.850.390.510.771.01
Total Current Assets14.2219.468.5513.5314.8518.96
Net Property, Plant & Equipment0.070.040.040.050.050.10
Total Investments and Advances-0.000.000.000.000.00
Other Assets0.000.000.010.010.010.01
Total Assets14.2919.508.6113.5914.9119.08
Short Term Debt Incl. Current Port. of LT Debt0.000.002.501.250.000.00
Accounts Payable1.022.071.681.161.131.91
Other Current Liabilities1.851.421.141.372.551.56
Total Current Liabilities2.873.495.313.783.683.48
Long Term Debt6.909.204.208.458.908.50
Provision for Risks Charges-0.000.000.000.000.00
Other Liabilities0.301.300.208.002.601.00
Total Liabilities10.0713.999.7120.2315.1812.98
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.235.51-1.10-6.64-0.276.10
Total Shareholders Equity4.235.51-1.10-6.64-0.276.10
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity4.235.51-1.10-6.64-0.276.10
Total Liabilities & Stockholders Equity14.2919.508.6113.5914.9119.08
Book Value Per Share0.120.90-0.35-2.15-0.092.18
Tangible Book Value Per Share0.120.90-0.35-2.15-0.092.18
Full-Time Employees---16--
Price to Book Ratio11.185.74-7.70-15.32-163.623.66
Return on Assets-103.47-110.10-115.11-177.10-148.18-104.03
Return on Equity-763.32-365.70-399.51-761.02-526.36-209.36
Return on Invested Capital-15.04-52.01160.72-594.80-90.41-40.79
Quick Ratio-5.581.613.584.045.45
Current Ratio4.965.581.613.584.045.45

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income--7.654.98-10.76-7.80-5.96
Depreciation-0.010.010.010.010.01
Other Funds (Non Cash)-4.11-10.246.782.540.56
Funds from Operations--3.54-5.26-3.97-5.25-5.38
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital--1.080.40-0.880.48-1.29
Cash from Operating Activities--4.62-4.86-4.85-4.78-6.67
Capital Expenditures-0.000.00-0.01-0.01-0.01
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.040.000.000.000.00
Purchase or Sale of Investments-0.001.507.153.520.14
Purchase of Investments-0.000.00-0.50-1.48-7.31
Sale Or Maturity of Investments-0.001.507.655.007.45
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities-0.041.507.153.510.13
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-15.030.003.750.820.00
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-15.030.003.750.820.00
Proceedsfrom Stock Options-12.030.003.750.790.00
Issuance or Reduction of Debt, Net-0.000.000.000.00-0.10
Change in Long Term Debt-0.000.000.000.00-0.10
Issuance of Long Term Debt-0.000.000.000.00-0.10
Reduction of Long Term Debt-0.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.00
Cash from Financing Activities-15.030.003.750.82-0.10
Net Change in Cash-10.45-3.366.05-0.45-6.64
Free Cash Flow--4.62-4.86-4.86-4.79-6.67

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.14%0.2M4.1M83.31K
2026-10-151.49%0.1M4.1M75.56K
2026-09-302.07%0.1M4.2M77.15K
2026-09-152.68%0.1M4.2M274.67K
2026-08-313.08%0.1M4.1M270.40K
2026-08-141.56%0.1M4.1M261.99K
2026-07-312.91%0.1M3.5M255.75K
2026-07-155.56%0.2M3.5M254.38K
2026-06-3022.54%0.3M1.5M245.68K
2026-06-152.98%0.1M1.9M47.41K
2026-05-291.56%0.0M1.9M54.27K
2026-05-151.38%0.0M2.0M60.68K
2026-04-301.92%0.0M1.7M83.19K
2026-04-154.51%0.1M1.7M255.01K
2026-03-314.46%0.1M1.5M249.99K
2026-03-136.06%0.1M1.5M244.33K
2026-02-275.18%0.1M1.5M220.54K
2026-02-136.17%0.1M1.4M214.62K
2026-01-3012.43%0.1M1.1M188.89K
2026-01-151.43%0.0M1.1M16.52K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-10-168-KCurrent report2026-10-15SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-308-KCurrent report2026-09-30SEC
2026-09-30424B5SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-23S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-168-KCurrent report2026-09-15SEC
2026-09-028-KCurrent report2026-08-31SEC
2026-08-278-KCurrent report2026-08-27SEC
2026-08-25SCHEDULE 13GSEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-24SCHEDULE 13D/ASEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-21SCHEDULE 13D/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06200.00K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Woodline Partners LP15.76%
HEIGHTS CAPITAL MANAGEMENT, INC9.85%
STEMPOINT CAPITAL LP7.88%
Squadron Capital Management LLC7.88%
Stonepine Capital Management, LLC3.94%
L1 Global Manager Pty Ltd1.58%
MORGAN STANLEY0.91%
RENAISSANCE TECHNOLOGIES LLC0.62%
VANGUARD CAPITAL MANAGEMENT LLC0.56%
180 WEALTH ADVISORS, LLC0.53%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.56%
Fidelity Extended Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.01%
Fidelity Series Total Market Index Fund0.01%
Fidelity Total Market Index Fund0.01%

OakChart. CALC. Cached 15 minutes.